William Blair Estimates CeriBell’s Q1 Earnings (NASDAQ:CBLL)

CeriBell (NASDAQ:CBLL) – Equities researchers at William Blair lowered their Q1 2025 EPS estimates for shares of CeriBell in a report issued on Wednesday, February 26th. William Blair analyst M. Andrew now expects that the company will earn ($0.44) per share for the quarter, down from their prior estimate of ($0.30). William Blair has a “Outperform” rating on the stock. The consensus estimate for CeriBell’s current full-year earnings is ($2.46) per share. William Blair also issued estimates for CeriBell’s Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.81) EPS, Q1 2026 earnings at ($0.37) EPS, Q2 2026 earnings at ($0.35) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.33) EPS and FY2026 earnings at ($1.40) EPS.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). The business had revenue of $18.53 million for the quarter, compared to analyst estimates of $17.55 million.

CBLL has been the topic of a number of other research reports. TD Cowen increased their price objective on shares of CeriBell from $31.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. JPMorgan Chase & Co. initiated coverage on shares of CeriBell in a report on Tuesday, November 5th. They set an “overweight” rating and a $32.00 price target on the stock. Bank of America initiated coverage on shares of CeriBell in a report on Tuesday, November 5th. They set a “buy” rating and a $32.00 price target on the stock. Canaccord Genuity Group initiated coverage on shares of CeriBell in a report on Tuesday, November 5th. They set a “buy” rating and a $30.00 price target on the stock. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $33.00 price target on shares of CeriBell in a report on Wednesday. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $32.60.

CeriBell Trading Down 2.2 %

NASDAQ:CBLL opened at $23.24 on Friday. CeriBell has a 1-year low of $18.69 and a 1-year high of $32.75. The business has a fifty day simple moving average of $23.34.

Hedge Funds Weigh In On CeriBell

Several hedge funds and other institutional investors have recently modified their holdings of the business. Woodline Partners LP purchased a new position in shares of CeriBell in the fourth quarter worth about $2,588,000. Yu Fan purchased a new position in shares of CeriBell in the fourth quarter worth about $31,631,000. TPG GP A LLC purchased a new position in shares of CeriBell in the fourth quarter worth about $102,677,000. RTW Investments LP purchased a new position in shares of CeriBell in the fourth quarter worth about $3,882,000. Finally, Red Tree Management LLC purchased a new position in shares of CeriBell in the fourth quarter worth about $57,083,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.